MA53322A - Anticorps procoagulants améliorés - Google Patents

Anticorps procoagulants améliorés

Info

Publication number: MA53322A
Authority: MA; Morocco
Prior art keywords: procoagulant antibodies; enhanced procoagulant; enhanced; antibodies; procoagulant
Prior art date: 2018-08-01

Application number

MA053322A

Other languages

English (en)

Inventor

Jianhe Chen

Per J Greisen

Bjarne Gram Hansen

Mikkel Nors Harndahl

Eva Johansson

Laust Bruun Johnsen

Morten Grønbech Rasch

Anders Svensson

Karina Thorn

Zhiru Yang

Rong Zhou

Haisun Zhu

Henrik Østergaard

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-08-01

Filing date

2019-07-31

Publication date

2021-11-10

2019-07-31 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2021-11-10 Publication of MA53322A publication Critical patent/MA53322A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA053322A 2018-08-01 2019-07-31 Anticorps procoagulants améliorés MA53322A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN2018097834		2018-08-01
CN2018099339		2018-08-08
EP18193191		2018-09-07

Publications (1)

Publication Number	Publication Date
MA53322A true MA53322A (fr)	2021-11-10

Family

ID=67480228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA053322A MA53322A (fr)	2018-08-01	2019-07-31	Anticorps procoagulants améliorés

Country Status (18)

Country	Link
US (1)	US20230058721A1 (fr)
EP (1)	EP3830135A1 (fr)
JP (3)	JP6761142B1 (fr)
KR (2)	KR102382743B1 (fr)
CN (3)	CN112513096B (fr)
AU (1)	AU2019313550B2 (fr)
CA (1)	CA3113797A1 (fr)
CL (2)	CL2021000186A1 (fr)
CO (1)	CO2021001046A2 (fr)
IL (1)	IL280239B1 (fr)
MA (1)	MA53322A (fr)
MX (1)	MX2021001064A (fr)
MY (1)	MY202203A (fr)
PE (1)	PE20211399A1 (fr)
PH (1)	PH12021550117A1 (fr)
SG (1)	SG11202100418PA (fr)
TW (1)	TWI716059B (fr)
WO (1)	WO2020025672A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021152066A1 (fr) *	2020-01-30	2021-08-05	Novo Nordisk A/S	Anticorps mimétiques bispécifiques du facteur viii
KR102839278B1 (ko)	2022-03-02	2025-07-30	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체의 월 1회 투여 방법
CN118786149A (zh) *	2022-03-02	2024-10-15	诺和诺德医疗保健公司	每两周施用fviii模拟双特异性抗体的方法
KR102868672B1 (ko) *	2022-03-02	2025-10-14	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
KR102839225B1 (ko) *	2022-03-02	2025-07-29	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체의 주 1회 투여 방법
KR102749341B1 (ko)	2022-07-08	2025-01-06	노보 노르디스크 에이/에스	FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
AU2023303873A1 (en)	2022-07-08	2025-01-02	Novo Nordisk A/S	Highly potent isvd compounds capable of substituting for fviii(a)
WO2024261245A1 (fr)	2023-06-23	2024-12-26	Novo Nordisk Health Care Ag	Procédés d'administration d'anticorps bispécifiques mimétiques de fviii une fois tous les deux mois
GB202408056D0 (en) *	2024-06-06	2024-07-24	Cambridge Entpr Ltd	Anticoagulant protein molecules and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
DK0979281T3 (da) *	1997-05-02	2005-11-21	Genentech Inc	Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
AT411997B (de) *	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en)	2003-09-12	2007-11-20	Baxter International Inc.	Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035754A1 (fr) *	2003-10-14	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	Anticorps a double specificite de substitution de proteine fonctionnelle
WO2005035753A1 (fr) *	2003-10-10	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	Anticorps a double specificite remplaçant une proteine fonctionnelle
EP2824183B1 (fr) *	2005-04-08	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Procédé pour la production d'anticorps bispécifiques
JP6013915B2 (ja) *	2010-11-17	2016-10-25	中外製薬株式会社	血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
EP2847228B1 (fr) *	2012-05-10	2018-07-25	Bayer Pharma Aktiengesellschaft	Anticorps capables de lier au facteur de coagulation xi et/ou à sa forme activée, le facteur xia, et utilisations de ceux-ci
WO2015067755A2 (fr) *	2013-11-07	2015-05-14	Novo Nordisk A/S	Nouvelles méthodes et nouveaux anticorps destinés au traitement d'une coagulopathie
TWI700300B (zh) *	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
JP6698102B2 (ja) *	2015-04-17	2020-05-27	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	凝固因子と多重特異的抗体を用いた併用療法
JP7227146B2 (ja) *	2016-11-23	2023-02-21	バイオベラティブセラピューティクスインコーポレイテッド	凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
CN110248964B (zh)	2017-02-01	2024-08-27	诺和诺德股份有限公司	促凝血抗体
US11220554B2 (en) *	2018-09-07	2022-01-11	Novo Nordisk A/S	Procoagulant antibodies

2019
- 2019-07-31 CN CN201980050877.2A patent/CN112513096B/zh active Active
- 2019-07-31 SG SG11202100418PA patent/SG11202100418PA/en unknown
- 2019-07-31 AU AU2019313550A patent/AU2019313550B2/en active Active
- 2019-07-31 MA MA053322A patent/MA53322A/fr unknown
- 2019-07-31 MY MYPI2021000234A patent/MY202203A/en unknown
- 2019-07-31 PE PE2021000121A patent/PE20211399A1/es unknown
- 2019-07-31 CA CA3113797A patent/CA3113797A1/fr active Pending
- 2019-07-31 JP JP2020506232A patent/JP6761142B1/ja active Active
- 2019-07-31 WO PCT/EP2019/070628 patent/WO2020025672A1/fr not_active Ceased
- 2019-07-31 CN CN202310977964.0A patent/CN117343188A/zh active Pending
- 2019-07-31 CN CN202310981355.2A patent/CN117384296A/zh active Pending
- 2019-07-31 KR KR1020217004977A patent/KR102382743B1/ko active Active
- 2019-07-31 KR KR1020217022278A patent/KR102887629B1/ko active Active
- 2019-07-31 EP EP19746091.8A patent/EP3830135A1/fr active Pending
- 2019-07-31 MX MX2021001064A patent/MX2021001064A/es unknown
- 2019-08-01 TW TW108127371A patent/TWI716059B/zh active
2020
- 2020-03-04 JP JP2020036964A patent/JP7094314B2/ja active Active
2021
- 2021-01-15 PH PH12021550117A patent/PH12021550117A1/en unknown
- 2021-01-18 IL IL280239A patent/IL280239B1/en unknown
- 2021-01-22 CL CL2021000186A patent/CL2021000186A1/es unknown
- 2021-01-29 CO CONC2021/0001046A patent/CO2021001046A2/es unknown
- 2021-11-10 US US17/522,949 patent/US20230058721A1/en active Pending
2022
- 2022-03-25 JP JP2022050042A patent/JP7355874B2/ja active Active
2025
- 2025-04-29 CL CL2025001281A patent/CL2025001281A1/es unknown

Also Published As

Publication number	Publication date
MY202203A (en)	2024-04-17
JP2020530449A (ja)	2020-10-22
KR20210091839A (ko)	2021-07-22
TWI716059B (zh)	2021-01-11
JP6761142B1 (ja)	2020-09-23
JP7094314B2 (ja)	2022-07-01
KR20210040389A (ko)	2021-04-13
PH12021550117A1 (en)	2021-10-04
PE20211399A1 (es)	2021-07-27
CL2025001281A1 (es)	2025-08-22
JP2022084858A (ja)	2022-06-07
MX2021001064A (es)	2021-04-12
CN112513096B (zh)	2023-08-25
EP3830135A1 (fr)	2021-06-09
WO2020025672A9 (fr)	2020-04-23
JP2020115863A (ja)	2020-08-06
US20230058721A1 (en)	2023-02-23
CN117384296A (zh)	2024-01-12
CO2021001046A2 (es)	2021-04-30
AU2019313550B2 (en)	2024-02-08
CL2021000186A1 (es)	2021-07-02
BR112021000823A2 (pt)	2021-04-13
IL280239A (en)	2021-03-25
KR102382743B1 (ko)	2022-04-12
AU2019313550A1 (en)	2021-02-04
CN117343188A (zh)	2024-01-05
JP7355874B2 (ja)	2023-10-03
CN112513096A (zh)	2021-03-16
WO2020025672A1 (fr)	2020-02-06
IL280239B1 (en)	2025-11-01
CA3113797A1 (fr)	2020-02-06
SG11202100418PA (en)	2021-02-25
TW202007696A (zh)	2020-02-16
KR102887629B1 (ko)	2025-11-19

Publication	Publication Date	Title
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
MA53322A (fr)	2021-11-10	Anticorps procoagulants améliorés
EP3784699A4 (fr)	2022-04-13	Anticorps anti-tl1a optimisés
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA46525A (fr)	2019-08-21	Anticorps anti-lag-3 et compositions
MA44659A (fr)	2021-04-14	Anticorps anti-tim-3 et compositions
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
EP3442579A4 (fr)	2019-12-18	Anticorps anti-vista humain et utilisation associée
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
MA52152A (fr)	2021-01-20	Anticorps
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3831851A4 (fr)	2022-04-27	Anticorps anti-btla
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb